What Albiglutide is
Albiglutide is a long-acting GLP-1 receptor agonist developed for metabolic disease management in approved contexts.
Albiglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it matters because it helps map the broader GLP-1 drug family beyond the few names dominating current culture.
The useful starting point is to separate the molecule itself from the internet story around it. It matters because it helps map the broader GLP-1 drug family beyond the few names dominating current culture.
Why people keep looking it up
It matters because it helps map the broader GLP-1 drug family beyond the few names dominating current culture.
Albiglutide is a long-acting GLP-1 receptor agonist developed for metabolic disease management in approved contexts.
Albiglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucose control, and long-acting incretin. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved GLP-1 medicine with clear human evidence for regulated uses.
Human trials and historical regulatory approval support specific labeled uses.
Mechanism is consistent with GLP-1 receptor pharmacology and incretin biology.
Why this page carries the current tier: Approved GLP-1 medicine with clear human evidence for regulated uses.
The current seed trail for Albiglutide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Even for approved GLP-1 medicines, contraindications and labeling context matter more than social-media summaries.
Albiglutide reached approved-drug status historically, though market presence and availability have changed over time.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Albiglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Albiglutide is CID 122173812. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 122173812
- Formula
- C148H223N39O46
- Molecular weight
- 3284.6
- InChIKey
- OGWAVGNOAMXIIM-VTAHJYCESA-N
Matched synonyms include albiglutidum, Albiglutida, RefChem:141, A10BJ04, Albiglutide (genetical recombination), 5E7U48495E, 782500-75-8, Albiglutide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Albiglutide returns 39 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Albiglutide returns 285 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.